Showing results (261-270 of 274) with videos related to
Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2018
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice GuidelineJulie R Brahmer, Christina Lacchetti, Bryan J Schneider, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline UpdateBryan J Schneider, Jarushka Naidoo, Bianca D Santomasso, et al.Nature Medicine|May 27, 2021
Cytokine release syndrome in a patient with colorectal cancer after vaccination with BNT162b2Lewis Au, Annika Fendler, Scott T C Shepherd, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2021
Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO GuidelineBianca D Santomasso, Loretta J Nastoupil, Sherry Adkins, et al.Cancer Cell|July 10, 2019
Genomic and Transcriptomic Determinants of Therapy Resistance and Immune Landscape Evolution during Anti-EGFR Treatment in Colorectal CancerAndrew Woolston, Khurum Khan, Georgia Spain, et al.Nature Communications|November 19, 2021
Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damagePietro Carotenuto, Francesco Amato, Andrea Lampis, et al.The Lancet. Oncology|March 7, 2018
Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable diseaseEmil Ter Veer, L Bengt van Rijssen, Marc G Besselink, et al.The Journal of Pathology|November 15, 2023
Genetic and immune landscape evolution in MMR-deficient colorectal cancerBenjamin R Challoner, Andrew Woolston, David Lau, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 20, 2024
Circulating microRNA Analysis in a Prospective Co-clinical Trial Identifies MIR652-3p as a Response Biomarker and Driver of Regorafenib Resistance Mechanisms in Colorectal CancerSomaieh Hedayat, Luciano Cascione, David Cunningham, et al.Journal of the National Cancer Institute|May 16, 2019
Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-AnalysisQuisette P Janssen, Stefan Buettner, Mustafa Suker, et al.Pageof 28